Literature DB >> 9286612

Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion.

K E Vanover1.   

Abstract

Two allosteric alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor positive modulators, 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine (1-BCP) and 1-(quinoxalin-6-ylcarbonyl)piperidine (CX516), and the antipsychotic drug, haloperidol, were tested for their ability to inhibit hyperactivity induced by amphetamine and dizocilpine in mice. Haloperidol (0.03-1.0 mg/kg) and 1-BCP (20.0-120.0 mg/kg) attenuated hyperactivity induced by both amphetamine and dizocilpine, with higher potency against amphetamine. CX516 (30.0-170.0 mg/kg), however, failed to attenuate amphetamine- and dizocilpine-induced hyperactivity up to a dose which decreased spontaneous locomotor activity. These results indicate that AMPA receptor positive modulators may not be uniform with regard to their effects on dopamine-mediated behaviors and their antipsychotic potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286612     DOI: 10.1016/s0014-2999(97)01103-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  A desensitization-selective potentiator of AMPA-type glutamate receptors.

Authors:  Masayuki Sekiguchi; Kaori Nishikawa; Shunsuke Aoki; Keiji Wada
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

2.  Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter.

Authors:  R R Gainetdinov; A R Mohn; L M Bohn; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 3.  Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.

Authors:  Mark D Black
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

4.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.